Kidney transplantation is the optimal mode of therapy for patients with end-stage renal disease (ESRD) and can be life-saving. Although survival of the transplanted kidney is >90% within the first year of transplantation, graft survival declines over time and is typically <60-70% by 5 years post-transplantation 1 . New data from a study that assessed the effects of blocking the renin-angiotensin-aldosterone system (RAAS) on transplant outcomes suggest that use of the angiotensin-converting-enzyme (ACE) inhibitor, ramipril, did not reduce the risk of renal dysfunction or death in renal transplant recipients 2 . This study has several shortcomings, however, including a failure to achieve the target sample size, which limits the conclusions that can be drawn from the results.
The causes of declining kidney graft function after the first year post-transplantation are incompletely understood, but include transplant nephropathy, recurrence of the original disease, graft rejection, development observational designs, retrospective analyses and, most importantly, a lack of long-term clinical end points including ESRD.
Knoll et al. have now reported the findings of a multicentre, multinational study that was designed to resolve this controversy 2 . They performed a double-blind randomized controlled trial in which 213 kidney transplant recipients were randomly assigned to receive placebo or 5 mg ramipril once daily for up to 4 years. Participants were then followed for an extended observation period of up to 4 years. The primary end point was the composite of a doubling of serum creatinine level, ESRD or death. The researchers also performed repeated measurement of glomerular filtration rate (GFR) using radio labelled ⁹⁹ m technetium-diethylenetriamine-pentaacetate ( 99m Tc-DTPA) clearance at 6 monthly intervals during the treatment period. The researchers found no difference in the primary composite outcome, death or rate of decline in GFR between the placebo and ramipril groups.
This study has many strengths including its randomized, placebo-controlled and multi centre design, the use of a composite outcome, the use of a target blood pressure of 130/80 mmHg for all patients, the inclusion of patients with proteinuria, and the use of an intention-to-treat analysis. Additional of de novo disease, and nephrotoxicity from calcineurin inhibitors and other drugs. Transplant nephropathy is a syndrome in which structural damage, with scarring of vascular, tubular and interstitial compartments of the allograft, leads to a progressive decline in kidney function. This syndrome is the most common cause of loss of allograft function.
Proteinuria is a well-established marker of risk of disease progression in native kidneys and in kidney allografts. Moreover, many studies indicate that proteinuria is a poor prognostic factor for the long-term survival of kidney transplants. Identifying the cause of protein uria and instituting treatment is therefore prudent. RAAS blockers provide reno protection in a wide variety of kidney diseases, including glomerulonephritides, polycystic kidney disease and those associated with diabetes mellitus and hypertension 3, 4 . Most kidney transplant recipients are hypertensive and receive calcineurin inhibitors, which can raise blood pressure and activate the RAAS, providing a rationale for RAAS blockade in this patient population. Whether RAAS blockers benefit kidney transplant recipients has, however, been difficult to demonstrate, and their use in this population is controversial. The overall findings from randomized controlled trials, observational studies and meta-analyses of RAAS blockade in kidney transplant recipients are inconclusive [5] [6] [7] [8] . However, these studies have been limited by small sample sizes, use of surrogate outcomes, Blockade of the renin-angiotensin-aldosterone system (RAAS) slows the progression of many forms of kidney disease, but whether this therapy is beneficial in kidney transplant recipients is unclear. A new randomized controlled trial suggests that RAAS blockade is not beneficial in the transplant setting, but the underpowered nature of this study limits its conclusions. Lara Crow/NPG strengths include the extended observation phase. The researchers are to be congratulated for designing and conducting a multi centre outcomes trial in this patient population. Unfortunately, however, the study failed to show an improvement in outcomes in patients treated with ramipril.
So why did this study fail? It suffered from a major problem that is commonly encountered in clinical trials -namely, it was underpowered to detect a potentially important treatment effect. As indicated in the methods section of the report, the trial required 528 participants to have 80% power to detect a 12% difference in the primary outcome; however, the trial only included 213 participants. Although the researchers made a valiant attempt to identify a potential benefit of ramipril by extending the follow-up period, they were doomed to fail by the low recruitment. Estimated event rates were not reported by the researchers, but lower than anticipated event rates plagued the largest randomized controlled trial of RAAS blockade conducted to date, in which Philipp et al. failed to show a benefit of candesartan on ESRD and cardiovascular events among transplant recipients 7 . Additional potential confounders in the report by Knoll et al. include important imbalances in comorbidities between the two treatment groups, for example, in the proportion of participants with diabetes and heart failure at baseline.
Clinical trials that demonstrated the ability of RAAS blockade to prevent ESRD in patients with diabetes mellitus were much larger than the study by Knoll et al., with the number of participants ranging from 419 to 1,715. In addition, although the dose response of blood pressure to ACE inhibition is relatively flat, the antiproteinuric effect is dose dependent, particularly in populations administered calcineurin inhibitors 9, 10 . It is unfortunate that Knoll et al. did not use a higher dose of ramipril in their study, as dose could have important effects on the study outcome. Also, one-third of participants assigned to receive ramipril discontinued the drug permanently about 1 year after randomization. This high proportion of drug discontinuation could have contributed to the null result of the study. Finally, the trial protocol was modified to increase recruitment and the study took 4 years to recruit 213 participants, an excessive period of time for a relatively small sample size.
In my opinion, the study by Knoll et al. is not definitive. A properly powered study with sufficient participants is needed to provide definitive evidence of the efficacy and safety of RAAS blockade in renal transplant recipients. Although well designed, this aspirational study failed to move the field forward in a meaningful way and is unlikely to result in changes to clinical practice or treatment guidelines. A study with a larger sample size and a more homogenous risk factor profile, for example a minimum of 300 mg/g of albuminuria, might have increased the likelihood of detecting a difference in important clinical outcomes. In addition, the researchers' assertion that it is improbable that ramipril would benefit a lower risk kidney transplant population is not well founded. The fact that their study was underpowered -recruiting less than half of the calculated sample size needed to show a meaningful effect -makes this conclusion untenable. To the contrary, a large, properly powered study in a lower risk population might indeed demonstrate a benefit of ramipril. Such a trial, using a surrogate end point such as a 40% decline in estimated GFR or a substantive increase in serum creatinine, should be considered for the kidney transplant population.
The nephrology community must unite to develop and implement successful recruitment methodologies for clinical trials to definitively answer the important question of whether RAAS blockade improves outcomes in kidney transplant recipients. Unfortunately, the study by Knoll et al. does not provide new insights into, nor settle the controversy surrounding the use of RAAS blockade in the renal transplant population. Until firm evidence is available to the contrary, RAAS blockers will therefore continue to be used to manage hypertension and proteinuria in renal transplant recipients.
